Bausch Health Discusses Strategic Options for Bausch + Lomb
During its third-quarter 2026 earnings call, Bausch Health Companies Inc. addressed potential strategic options regarding its ownership stake in Bausch + Lomb Corporation.
Stocks · News reference
FactSet Analyst Survey Updates Bausch + Lomb EPS Forecast and Price Target
A recent survey of 14 analysts by FactSet has resulted in an upward revision of Bausch + Lomb Corporation's 2026 earnings per share (EPS) estimate and price target.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Bausch + Lomb SVP and CAO Frederick Munsch Sells Shares
Frederick Munsch, Senior Vice President, Controller, and Chief Accounting Officer of Bausch + Lomb, sold 112,015 common shares for approximately $2.29 million.
HC Wainwright Downgrades Bausch + Lomb to Neutral from Buy
HC Wainwright & Co. has downgraded Bausch + Lomb Corporation from Buy to Neutral while increasing its price target to $22 from $21.
Wells Fargo Maintains Equal-Weight on Bausch & Lomb, Raises Price Target to $19
Analysts Raise Price Targets for Bausch + Lomb Following Q3 Earnings
Multiple financial institutions, including RBC, Leerink Partners, and Jefferies, increased their price targets for Bausch + Lomb on October 29, 2026, following the company's third-quarter earnings report.
Bausch + Lomb Announces Publication of Multinational Survey Results on Dry Eye
Bausch + Lomb has published findings from a multinational survey that examines consumer perspectives, symptoms, and interactions with healthcare professionals regarding dry eye.